Pharvaris (PHVS) Wells Fargo 21st Annual Healthcare Conference summary

Company overview and scientific foundation

• Focused on developing deucrictibant, the first and only orally available B2 receptor antagonist for hereditary angioedema (HAE), addressing a significant unmet need for oral therapy options.

• Deucrictibant offers a longer half-life than previous therapies, enabling both prophylactic and on-demand use.

• The molecule provides rapid onset, once-daily dosing, and flexibility, allowing quick initiation and discontinuation as needed.

• High efficacy and tolerability, combined with oral convenience, aim to maximize disease control for HAE patients.

Phase III data and efficacy insights

• Recent phase III data for prophylactic use showed 87% attack reduction in type 1 and 2 HAE patients, matching injectable therapies.

• The primary endpoint in the overall study was 83% attack reduction, including patients with normal C1.

• The trial included a diverse, global patient population across six continents, addressing high unmet needs worldwide.

Safety profile and liver enzyme observations

• Two cases of liver enzyme elevation were observed, both without symptoms or bilirubin elevation, and with confounding factors such as fatty liver or long-term androgen use.

• Incidence and management of liver enzyme elevations are comparable to other approved prophylactic HAE therapies.

• No additional medical monitoring is expected, and the safety profile is anticipated to align with existing treatments.